Tumor targeting with ^99m Tc radiolabeled peptides: Clinical application and recent development

Area of Science:

• Nuclear oncology
• Radiopharmaceutical science
• Molecular imaging

Background:

• Targeting cancer cell receptors with radiolabeled peptides is a key area in nuclear oncology.
• Peptides offer advantages like small size, ease of preparation, and straightforward radiolabeling with minimal toxicity.
• The success of ¹¹¹ In-octreotide has spurred development of other receptor-targeting peptides for imaging.

Purpose of the Study:

• To review the potential of ^99m Tc-labeled peptides for tumor imaging.
• To highlight clinical and preclinical applications of these radiolabeled peptides.

Main Methods:

• Review of existing literature on radiolabeled peptides for cancer imaging.
• Focus on peptides labeled with technetium-99m (^99m Tc).
• Discussion of various receptor-targeting peptides under development or in clinical trials.

Main Results:

• ^99m Tc-labeled peptides are valuable tools for tumor targeting due to their favorable properties.
• Several peptide classes, including bombesin analogues and RGD peptides, are being investigated.
• Commonly used radionuclides for imaging include ^99m Tc and ¹¹¹ In (SPECT), and ⁶⁸ Ga and ¹⁸ F (PET).

Conclusions:

• ^99m Tc-labeled peptides show significant potential for radionuclide imaging of tumors.
• These agents are crucial for advancing diagnostic capabilities in nuclear oncology.
• Continued research into peptide-based radiopharmaceuticals will enhance cancer detection and management.